Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy
نویسندگان
چکیده
منابع مشابه
Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure
In this issue (P94), Kutoh reports type 2 diabetic patients who showed changes in cardiac function which is concomitant with changes in ketone bodies by using one of sodium glucose cotransporter 2 inhibitors (SGLT2i), tofogliflozin [1], proposing a possible mechanism for SGLT2i-mediated prevention of heart failure. EMPA-REG OUTCOME trial showed a striking relative risk reduction in hospitalizat...
متن کاملMetabolic ketoacidosis with normal blood glucose: A rare complication of sodium–glucose cotransporter 2 inhibitors
Ketoacidosis is a significant and often a life-threatening complication of diabetes mellitus seen mostly in type 1 diabetes mellitus as well as occasionally in type 2 diabetes mellitus. Diabetic ketoacidosis usually manifests with high blood glucose more than 250 mg/dL, but euglycemic diabetic ketoacidosis is defined as ketoacidosis associated with blood glucose level less than 250 mg/dL. Norma...
متن کاملEuglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
OBJECTIVE Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are the most recently approved antihyperglycemic medications. We sought to describe their association with euglycemic diabetic ketoacidosis (euDKA) in hopes that it will enhance recognition of this potentially life-threatening complication. RESEARCH DESIGN AND METHODS Cases identified incidentally are described. RESULTS We identif...
متن کاملImpact of sodium–glucose cotransporter 2 inhibitors on blood pressure
SGLT2 inhibitors are glucose-lowering agents used to treat type 2 diabetes mellitus (T2DM). These agents target the kidney to promote urinary glucose excretion, resulting in improved blood glucose control. SGLT2-inhibitor therapy is also associated with weight loss and blood pressure (BP) lowering. Hypertension is a common comorbidity in patients with T2DM, and is associated with excess morbidi...
متن کاملCardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.
The mechanism of action of empagliflozin in reducing the risk of adverse cardiovascular outcomes vs placebo in patients with type 2 diabetes mellitus and a high risk of cardiovascular disease in the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) trial is currently unknown. An antiatherosclerotic effect is consider...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Diabetes Research
سال: 2018
ISSN: 2314-6745,2314-6753
DOI: 10.1155/2018/6807219